Ensysce Biosciences Inc
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR)… Read more
Ensysce Biosciences Inc (ENSC) - Total Liabilities
Latest total liabilities as of September 2025: $2.30 Million USD
Based on the latest financial reports, Ensysce Biosciences Inc (ENSC) has total liabilities worth $2.30 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Ensysce Biosciences Inc - Total Liabilities Trend (2017–2024)
This chart illustrates how Ensysce Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Ensysce Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Ensysce Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Asia Biomass Public Company Limited
BK:ABM
|
Thailand | ฿714.88 Million |
|
Altura Mining Limited
PINK:ALTAF
|
USA | $4.88 Million |
|
Nocera Inc
NASDAQ:NCRA
|
USA | $1.04 Million |
|
Techindia Nirman Limited
NSE:TECHIN
|
India | ₹731.78 Million |
|
Athena Resources Ltd
AU:AHN
|
Australia | AU$191.63K |
|
Kim Hin Joo
KLSE:0210
|
Malaysia | RM19.07 Million |
|
Merafe
JSE:MRF
|
South Africa | ZAC1.10 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down Ensysce Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.73 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.92 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.72 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ensysce Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ensysce Biosciences Inc (2017–2024)
The table below shows the annual total liabilities of Ensysce Biosciences Inc from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $2.22 Million | -34.00% |
| 2023-12-31 | $3.36 Million | -66.12% |
| 2022-12-31 | $9.91 Million | -59.66% |
| 2021-12-31 | $24.58 Million | +250.56% |
| 2020-12-31 | $7.01 Million | -32.19% |
| 2019-12-31 | $10.34 Million | +38.95% |
| 2018-12-31 | $7.44 Million | +3.96% |
| 2017-12-31 | $7.16 Million | -- |